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A B S T R A C T
Cervical cancer is the second most common cancer in women worldwide. There are about 60,000 newly detected cases
and 30,000 deaths annually in Europe, with the highest incidence reported from Eastern Europe countries. According to
data from the National Institute of Public Health, in Croatia the incidence of cervical cancer was 14.9/100,000 in 2006,
ranking eighth most common malignancy in women. Croatia has a lower incidence of the disease compared to many
countries of Central and Southeast Europe. A large study carried out in 1995 by the International Agency for Research
on Cancer, which included cervical cancer material collected from 22 countries all over the world revealed HPV genome
in 99.7% of cases. Efficient methods of cervical cancer detection and screening methods for identification of precancerous
lesions (conventional Pap smear) are available. Cervical cancer prevention programs should include education (of health
care providers and women), stressing the benefits of screening, the age of the peak cervical cancer incidence, and the
signs and symptoms of precancerous lesions and invasive disease. The aim of screening actions is to detect precancerous
lesions that may lead to cancer if left untreated. Screening can only be effective if there is a well-organized system of fol-
low up, diagnosis and treatment. Cervical cytology, or Papanicolaou (Pap) testing, has for decades been a cornerstone of
cervical cancer screening. According to recent guidelines issued by the World Health Organization Regional Office for
Europe, the primary task of the public health system is the introduction of secondary prevention through properly orga-
nized screening programs. Launching the national immunization program is only possible in the countries with well-or-
ganized secondary prevention programs and in those that can afford it.
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Introduction
Cervical cancer is the second most common cancer in
women worldwide. There are 500,000 new cases and
270,000 deaths recorded in the world per year. The high-
est incidence of the disease has been reported from devel-
oping countries of South-West Africa, South America and
South-East Asia (Figure 1). Nearly 80% of newly de-
tected cases of cervical cancer are reported from these
countries1. In Europe, there are about 60,000 newly de-
tected cases and 30,000 deaths per year, with the highest
incidence of the disease in the Eastern Europe coun-
tries2–5.
Cervical Cancer Trends in the EU
In the European Union (EU), the incidence of cervical
cancer is 4.0/100,000 to up to 29.9/100,000 women in the
EU eastern member countries6. Analysis of cervical can-
cer mortality in 25 EU member countries showed the in-
cidence to be lowest in Finland and highest in Lithua-
nia2. The risk of developing cervical cancer increases
with age and reaches peak at about 35 to 55 years of age
in unscreened populations7.
According to the International Agency for Research
in Cancer (IARC) data for 2004, there were 34,300 newly
registered cervical carcinoma cases in 27 EU member
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countries and 16,300 women died from the disease. The
EU countries before 2005 enlargement had a lower inci-
dence of the disease thanks to organized screening pro-
grams. In these countries, cervical carcinoma ranked
tenth of all cancers in women. The highest cervical can-
cer mortality is found in Romania (13.7/100,000) and
lowest in Finland (1.1/100,000). With the exception of
Malta, 11 new EU member countries have a higher cervi-
cal carcinoma prevalence and mortality than old EU
member countries (Figure 2)5.
Therefore Candice Pettifer concludes:
¿ cervical cancer remains an important problem in
the EU,
¿ the primary cause of cervical cancer is a persistent
infection with a cancer-causing genital human pa-
pillomavirus (HPV),
¿ HPV infections are very common and acquired soon
after onset of sexual activity,
¿ most HPV infections clear spontaneously,
¿ persistent HPV infections with a high-risk type can
cause cellular changes that can result in cervical
cancer,
¿ HPV 16 and 18 are together associated with an esti-
mated 73% of cases of cervical cancer in Europe,
and
¿ cervical cancer can be prevented by screening and
treating precancerous lesions7.
According to data from the National Institute of Pub-
lic Health, in 2006 the incidence of cervical cancer was
14.9/100,000 in Croatia, with cervical cancer ranking
eighth most common malignant disease in women. Cro-
atia has a lower incidence of the disease as compared to
many countries of Central and Southeast Europe (Figure
3). The mortality from cervical cancer in Croatia is esti-
mated to 4.3/100,000 women8.
Cervical carcinoma is a disease of younger women.
The highest incidence is found in the 35–50 age group. In
the population of women aged 25–40, cervical cancer is
the second most prevalent malignancy, just behind breast
cancer. Given that today, women often decide to accom-
plish their reproduction after their thirties, one can say
that this disease seriously affects human procreation
(Figure 4).
The Etiopathogenesis of
Cervical Carcinoma
A large study carried out by IARC in 1995 on cervical
cancer material collected from 22 countries all over the
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Fig. 1. Incidence of cervical carcinoma worldwide1.
Fig. 2. Incidence of cervical cancer in European countries
(on 100 000 women) standardized by age5.
Fig. 3. The geographic distribution of cervical cancer mortality
– age standardized rate (mortality /100 000 woman-year)
(W-ASMR World age-standardized mortality) in 11 countries
of SouthEast Europe, the estimates for year 2002/20042,5,9.
Fig. 4. Incidence of cervical cancer in young European women
(aged 15–44) (source: Ferlay J et al. Lyon, France: IARC Press,
2004)5.
world revealed HPV genome in 99.7% of cases10. Subse-
quent IARC meta-analysis on 13,000 cervical cancer spe-
cimens showed the presence of eight most common high-
-risk oncogenic HPV strains, i.e. HPV 16, 18, 45, 31, 33,
52, 58 and 35. These eight high-risk strains are responsi-
ble for about 90% of all cervical carcinoma cases. Subse-
quent study confirmed the HPV 16 and 18 strains to be
responsible for about 70% of cervical carcinoma of squa-
mous origin and 86% of adenocarcinoma5. HPV is a small
DNA virus that has a circular genome consisting of sev-
eral thousand base pairs incorporated into icosahedral
capsid surrounded by two capsid proteins L1 and L2 (Fig-
ure 5). More than 100 HPV types have been isolated to
date, with about 40 of them able to cause infection of the
anogenital mucous membranes. They primarily infect
the superficial layer of squamous epithelium of the skin
and mucous membranes11,12.
Genital HPV strains are divided into three groups, as
follows:
¿ high-risk oncogenic strains (16, 18, 31, 33, 35, 39,
45, 51, 52, 56, 58 and 59),
¿ possibly carcinogenic strains (26, 53, 66, 68, 73 and
82), and
¿ low-risk oncogenic strains (6, 11, 40, 42, 43, 44, 54,
61, 70, 72, 81 and 89).
The latter can cause benign proliferation of epithe-
lium of the anogenital region but these changes are not
associated with cervical carcinoma13.
The Significance of Persistent
HPV Infection
HPV infection is the most common sexually transmit-
ted disease. Many studies using HPV DNA testing in
asymptomatic women show the prevalence of HPV infec-
tion in the general population to be 2–44%14. This large
difference in the prevalence results from different popu-
lation groups studied as well as from variation in molecu-
lar sensitivity of different methods used on HPV DNA
detection. Many epidemiologic studies have shown the
prevalence of HPV infection to be highest in sexually ac-
tive women younger than 25, then abruptly declining to
the age of 45–50, when the second prevalence peak oc-
curs15,16 (Figure 6)17.
This second prevalence peak at peri- and postmeno-
pause can be explained by the following:
¿ reactivation of prior latent infection,
¿ new infection with a new partner,
¿ changes in sexual behavior in recent decades may
have an effect on HPV exposure, and
¿ infection in different cohorts of women examined
(cohort effect).
HPV infection will resolve spontaneously in 90–95%
of cases. For precancerous lesions of the cervix (cervical
intraepithelial neoplasm, CIN) and cervical cancer to de-
velop, permanent infection with a high-risk HPV strain
is required. Yet, there is no consensus on what is ‘perma-
nent infection with HPV. Recent studies show that a
woman that is positive for infection with a high-risk
oncogenic HPV strain will show a tendency to develop
precancerous lesion of the cervix in 6–12 months16–19.
Risk Factors for HPV Infection
According to numerous prospective studies, the risk
of HPV infection increases with:
¿ early age at first sexual activity,
¿ large number of partners,
¿ cigarette smoking,
¿ use of oral contraceptives,
¿ association with other sexual infections (Chlamy-
dia trachomatis, Herpes simplex virus type II),
¿ chronic inflammation of the lower genital tract, and
¿ immunosuppressive states.
According to some findings, the use of condoms may
reduce the risk of HPV infection by up to 70%. However,
other studies show that the use of condoms may increase
the risk of developing HPV infection. People usually use
condoms with partners that they expect to be at an in-
creased risk of STD (a new partner, a prostitute), but not
with a partner with which they expect safe sex (a long-
-term partner, a spouse). This mode of behavior may ex-
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Fig. 5. Ikoshaedral structure of HPV virus13.
Fig. 6. Prevalence of HPV infection according to ager17.
plain the results of some studies where the use of con-
doms did not reduce the risk of HPV infection20–22. A few
studies suggest that food rich in fruit and vegetables,
high doses of vitamins C and E, and alpha and beta caro-
tene may reduce the risk of HPV infection20–22. There is a
well-known fact that the infection with high-risk onco-
genic HPV strain need not necessarily lead to neoplastic
conversion, which indicates the possible role of the host’s
immune system. The host’s immune system can cause vi-
rus elimination; however, if the immune mechanism of
the host is inadequate to eliminate the virus, the infec-
tion can become permanent and lead to precancerous le-
sion of the cervix and finally to cancer. It is possible that
the human leukocyte antigen (HLA) system gene plays
an important role in the emergence of persistent HPV in-
fection. Specifically, protein products of HLA genes play
an important role in antigen presentation to T cells of
the host. In two separate studies, Maciag et al.23 and
Wang and Hildesheim24 isolated different haplotypes of
HLA II system. Some of these haplotypes were found to
reduce the risk of persistent HPV infection three to four
times, whereas carriers of other haplotypes had up to
sevenfold risk of developing persistent HPV infec-
tion23,24. Permanent infection with high-risk oncogenic
HPV strains causes changes in epithelial cells that can be
mild (low-grade squamous intraepithelial lesions, LSIL)
or severe (high-grade squamous intraepithelial lesions,
HSIL). Preinvasive lesions are relatively easily treated
with ablative surgical procedures (conization with cold
knife or LLETZ). It is assumed that persistent infection
with HPV leads to invasive cancer of the cervix in 7–10
years. Thus, there is enough time for preventive actions.
The natural course of the disease from persistent infec-
tion with high-risk HPV strain to the development of cer-
vical cancer is shown in Figure 717.
Theoretically, cervical cancer is a disease that should
not be permitted to develop in any woman and no woman
should die from it. Cervix is an organ available to direct
visualization on gynecologic examination. There are effi-
cient methods of cervical cancer detection and screening
methods for precancerous lesion identification (conven-
tional Papanicolaou (Pap) smear).
Cervical cancer prevention programs should include
education (of health care providers and women) that
stresses the benefits of screening, the age of peak cervical
cancer incidence, and the signs and symptoms of precan-
cerous lesions and invasive disease25. Screening aims to
detect precancerous changes that may lead to cancer if
left untreated. Screening is only effective if there is a
well-organized system for follow up, diagnosis and treat-
ment.
The World Health Organization (WHO) recommends
specific target ages and frequency of cytologic screening:
¿ new programs should start screening women at age
30 or older, and should only screen younger women
when the older age groups have been adequately
screened; the existing programs should not screen
women younger than 25;
¿ if a woman can undergo screening only once in her
lifetime, the best age is between 35 and 45;
¿ in women aged over 50, a five-year screening inter-
val is appropriate;
¿ in women aged 25–49, a three-year interval can be
considered if resources are available;
¿ annual screening is not recommended at any age;
¿ screening is not necessary in women aged over 65,
provided the last two previous smears in mid-life
were negative.
Table 1 shows WHO recommendations for primary
and secondary prevention of cervical carcinoma25.
Regular cervical cancer screening is especially impor-
tant in women with HIV infection because they are at a
higher risk of acquiring oncogenic HPV types, and being
infected with HPV, they are at a higher risk of rapid pro-
gression to precancerous lesions and cancer26.
Cervical cytology or Pap testing has been a corner-
stone of cervical cancer screening for decades. Most cer-
vical cancer cases and deaths can be prevented by cyto-
logic screening followed by appropriate diagnosis and
treatment27,28. It has been demonstrated in countries
with well-organized screening programs or extensive op-
portunistic screening with effective follow-up for pa-
tients with abnormal or borderline smears, quality con-
trol procedures and high coverage29.
Many countries use different methods of cervical can-
cer screening depending on the level of development and
gross national product (GNP). Table 2 shows the most
widely used methods of screening and assessment and
their sensitivity and specificity30.
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Fig. 7. Natural course of permanent HPV infection to cervical
carcinoma17; HPV – Human papillomavirus, HSIL – High-
-grade Squamous Intraepithelial Lesion, LSIL – Low-grade
Squamous Intraepithelial Lesion, BM – Basal Membrane, HLA
– Human Leukocyte Antigen.
The Situation in Croatia
The conventional Pap smear has been widely used
since 1962, although the first laboratory of gynecologic
cytology was founded in 1953. Croatia has a good model
of public health and sufficient number of gynecologists
and cytologists. Croatia is one of the few countries in Eu-
rope that have residency in cytology that includes post-
graduate study in gynecologic cytology31. However, in the
last ten years Croatia has a 'stable' incidence of cervical
cancer of 14–16/100,000 women. This figure has been at-
tributed to the opportunistic screening program used in
Croatia. Women present for Pap smears on their on ini-
tiative, mainly involving the same group of women. We
assume that only 30–35% of the female population are
covered by opportunistic screening, while a large propor-
tion of women are not included in the screening, and it is
the group where 90% of cervical cancer cases are found.
Therefore, it is necessary to launch an organized screen-
ing program as soon as possible, in which we will be com-
mitted by conclusions of the ministers of EU Health
Council Committee from 1994. At that meeting it was
concluded that there was a sufficient body of scientifi-
cally based data to justify the introduction of organized
screening program for breast and cervical cancer in wo-
men and for colon cancer in women and men. During
2003, the national health ministers of all EU member
countries adopted a document on the need of an orga-
nized screening program, thus pointing to organized can-
cer control in Europe. With a well organized cancer
screening program, cervical cancer can be reduced by
80%32,33. The Working Group of the Ministry of Health
and Social Welfare of Croatia made a proposal for early
detection of cervical cancer in Croatia. The program pro-
posed clearly indicates the objectives of the program, pro-
gram organization, technical performance, as well as
evaluation and monitoring of the program. We believe
that in the near future the Ministry of Health and Social
Welfare will accept our proposal34.
HPV Vaccines
Secondary prevention now poses the issue of primary
prevention. Researchers have isolated the genome of the
HPV gene encoding protein L1. Installation of this gene
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TABLE 1
WHO RECOMMENDATIONS FOR PREVENTION AND CONTROL OF CERVICAL CANCER CAUSED BY HPV INFECTION25
Primary prevention Early detection and screening Treatment
Reduce high-risk sexual behaviours Periodic screening using: cytology
(Pap test) for women aged 25+ years,
preferably in organized programmes
Precancerous lesions: cryotherapy, loop
electrosurgical excision procedure, or
surgical excision.
Condom use In pilot or carefully monitored settings
periodic screening with: HPV DNA tests;
or visual inspection of cervix with acetic
acid or Lugol’s iodine
»Screen and treat« in low-resource
settings using cryotherapy
Cancer: surgery, chemotherapy, radiother-
apy, brachytherapy, paliative care
Avoid or reduce tobacco use
Seek prompt treatment of sexually
transmitted infections
Prompt diagnostic follow-up if screening
test abnormal (e.g. colposcopy and biopsy)
TABLE 2
CHARACTERISTICS OF SCREENING TESTS FOR SECONDARY PREVENTION (SOURCE SANKARANARAYAN ET AL. 2005) 30
Characteristics Conventionalcytology
HPV DNA
tests
Visual inspection test
VIA VILI
Sensitivity 47–62% 66–100% 67–79% 78–98%
Specificity (for high –
grade lesions and
invasive cancer)
60–95% 62–96% 49–86% 73–91%
Comments Assessed over the last 50
years in a wide range of
settings in developed and
undeveloped countries
Assessed over the last
decade in many settings
in developed countries
and a few developing
countries
Assessed over the last
decade in many settings
in developing countries
Assessed by IARC over
the last four years in
India and three countries
in Africa. Need
further evaluation for
reproducibility
Number of visits
required for screening
and treatment
Two or more Two or more Can be used in a single-visit or see-and treat
approach where outpatient treatment is available
IARC – International Agency for Research on Cancer, VIA – visual inspection with acetic acid application; VILI – visual inspection
with Lugol’s iodine
in the appropriate expressional systems enabled produc-
tion of L1-virus like particles (L1-VLP). L1-VLP is con-
formationally identical to the natural virus containing
the viral epitopes of capsid making it antigenic even if it
does not contain the genome of HPV. The process from
conclusion to vaccine took ten years.
Currently, two HPV vaccines are licensed and marke-
ted35:
¿ one manufactured by Merck & Co. (known by the
brand name Gardasil), first licensed in 2006 and
here referred to as the »quadrivalent vaccine«; and
¿ one manufactured by GlaxoSmithKline (known as
Cervarix), first licensed in 2007.
By March 2008, both vaccines were licensed in several
countries for use in girls and women. Differences be-
tween the two vaccines are shown in Table 329. Both vac-
cines have been registered in Croatia and are available
on the market. Both vaccines are equally effective in pro-
tection against HPV infection. According to recent guide-
lines issued by the WHO Regional Office for Europe, the
primary task of the public health system is the introduc-
tion of secondary prevention through well-organized scre-
ening programs. Organization of a national immuniza-
tion program is only possible in countries with well-orga-
nized secondary prevention programs and in those that
can afford it18,36,37.
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TABLE 3
QUADRIVALENT AND BIVALENT HPV VACCINE CHARACTERISTICS29
Quadrivalent vaccine Bivalent vaccine
Manufacturer and trade name Merck; Gardasil® GlaxoSmithKline; Cervarix®
Virus-like particles of genotypes 6, 11, 16, 18 16, 18
Substrate Saccharomyces cerevisiase Baculovirus expression system
54 Adjuvant Proprietary aluminium hydroxyphosphate
sulfate (225mg) (Merck aluminium
adjuvant)
Proprietary aluminium hydroxide (500 mg)
plus 50 mg 3-deacylated monophospohoryl
lipid A (GSK AS04 adjuvant)
Schedule. 3 doses at intervals of 2 months between doses 1 and 2
6 months between doses 1 and 3
1 months between doses 1 and 2
6 months between doses 1 and 3
A. ]oru{i}
Department of Obstetrics and Gynecology, School of Medicine, University of Zagreb, Petrova 13, 10 000 Zagreb, Croatia
e-mail: ante.corusic@mef.hr
KARCINOM CERVIKSA KAO JAVNOZDRAVSTVENI PROBLEM – KAKO DALJE?
S A @ E T A K
Karcinom vrata maternice drugi je naj~e{}i karcinom u `ena u svijetu. U Europi se godi{nje otkrije oko 60 000
novooboljelih i oko 30 000 `ena umre od ove bolesti. Najve}a incidencija je u zemljama isto~ne Europe. U Hrvatskoj
prema podatcima Hrvatskog zavoda za javno zdravstvo (HZJZ) incidencija je 2006. godine bila 14.9 i po u~estalosti je na
osmome mjestu svih malignoma u `ene. Hrvatska ima ni`u incidenciju ove bolesti od mnogih dr`ava srednje i jugo-
isto~ne Europe. Veliko istra`ivanje International Agency for Research in Cancer (IARC) iz 1995. godine na materijalu iz
22 zemlje diljem svijeta otkrilo je u 99,7% svih karcinoma vrata maternice genom HPV-a. Danas postoje dobre metode
otkrivanja ove bolesti kao i dobra metoda probira (konvencionalni PAPA-obrisak). Program prevencije karcinoma vrata
maternice mora uklju~ivati edukaciju (za zdravstvene radnike i `ene) o dobrobiti programa probira, vr{noj dobi pojave
karcinoma kao i edukaciju o znakovima i simptomima preinvazivnih i invazivnih promjena. Programi probira su usmje-
reni prema preinvazivnim lezijama koje mogu dovesti do invazivnih ako se ne lije~e. Probir je u~inkovit samo ako
postoji dobro organiziran sustav pra}enja, dijagnostike i lije~enja. Citologija cerviksa ili Papanicolau obrisak temeljna je
metoda probira za karcinom vrata maternice kroz desetlje}a. Prema zadnjim smjernicama Europskog odjela Svjetske
zdravstvene organizacije primarna zada}a javnoga zdravstvenog sustava je uvo|enje sekundarne prevencije dobro
organiziranim programima probira. Organizaciju nacionalnih imunizacijskih programa mogu}e je aplicirati samo u
zemljama s dobro organiziranim programima sekundarne prevencije i u zemljama koje to mogu platiti.
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